Generic Drug Study

ICR 200102-3084-001

OMB: 3084-0122

Federal Form Document

Forms and Documents
Document
Name
Status
No forms / supporting documents in this ICR. Check IC Document Collections.
IC Document Collections
IC ID
Document
Title
Status
32344
Migrated
ICR Details
3084-0122 200102-3084-001
Historical Active
FTC
Generic Drug Study
New collection (Request for a new OMB Control Number)   No
Regular
Approved without change 04/06/2001
Retrieve Notice of Action (NOA) 02/22/2001
No OMB comment
  Inventory as of this Action Requested Previously Approved
12/31/2002 12/31/2002
100 0 0
45,000 0 0
45,000 0 0

The FTC proposes to seek information from members of the pharmaceutical industry in order to provide a more complete picture of how generic drug competition has developed under the Hatch-Waxman Act. The FTC plans to send special orders to approx. 30 innovator companies (i.e., name-brand drug makers) and 70 generic drug companies to examine agreements, etc., affecting drug competition.

None
None


No

1
IC Title Form No. Form Name
Generic Drug Study

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 100 0 0 100 0 0
Annual Time Burden (Hours) 45,000 0 0 45,000 0 0
Annual Cost Burden (Dollars) 45,000 0 0 45,000 0 0
Yes
No

$0
No
No
Uncollected
Uncollected
Uncollected
Uncollected

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
02/22/2001


© 2024 OMB.report | Privacy Policy